Loading…
Employees: 147
Size Aquestive Therapeutics (AQST) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $454M, the 2770th largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.61 on 6 Nov 2026.
Performance Over six months the shares fell 16.4%, against -13.1% for the median peer and -1.1% for the United States market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 12.5% over the last twelve months (peer median -4.9%); the operating margin is -114.1% (peer median 5.0%).
Valuation It trades at 10.5× enterprise value to sales against a peer median of 3.5× (3rd most expensive of 21).
Short interest Short interest is 22.0% of the free float (15 Oct 2026).
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $48.8M | $44.5M | $57.6M | $50.6M | $47.7M |
| Revenue growth | — | -23% | +14% | +6% | — |
| Gross profit | $31.9M | $27.4M | $39.7M | $30.0M | $27.8M |
| EBITDA | -$55.2M | -$69.1M | -$30.1M | -$13.5M | -$39.7M |
| Net income | -$79.3M | -$83.8M | -$44.1M | -$7.87M | -$54.4M |
| Free cash flow | -$40.7M | -$53.0M | -$35.9M | -$7.38M | -$10.8M |
| Capital expenditure | $933,000 | $562,000 | $159,000 | $995,000 | $2.52M |
| Total debt | $150M | $131M | $122M | $98.8M | $123M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AQST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.2% | -11.3% | 2nd lowest of 20 |
| 6-month return | -16.4% | -13.1% | 10th lowest of 20 |
| Distance from 52-week high | -47.3% | -37.9% | 6th lowest of 20 |
| Revenue growth (TTM) | +12.5% | -4.9% | 5th highest of 21 |
| Operating margin | -114.1% | 5.0% | lowest of 21 |
| EV / Sales | 10.5× | 3.5× | 3rd most expensive of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics AQST | United States | $454M | -16% | +13% | -114% | 10.5× | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $454M | +44% | +17% | 14% | 4.4× | n/a | n/a |
| Beijing Foyou Pharma 601089.SS | China | $455M | -24% | +5% | 10% | 0.2× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | 6.0× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $450M | +4% | -21% | 8% | 4.3× | 23.7% | +28.2% |
| Evolus EOLS | United States | $449M | +7% | +14% | -7% | 1.8× | n/a | n/a |
| RPG Life Sciences RPGLIFE.NS | India | $448M | +2% | +12% | 18% | 5.8× | n/a | n/a |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $463M | -21% | +7% | 19% | 3.6× | 7.1% | +1.3% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | 2.4× | 2.5% | -1.3% |
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | 10.4× | 33.5% | -0.9% |
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 3.5× | 26.6% | +8.0% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | 9.0× | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | 14.5× | 46.5% | -1.5% |
| Synmosa Biopharma 4114.TWO | Taiwan | $442M | +2% | +11% | 11% | 2.5× | 6.5% | +15.3% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | 4.5× | n/a | n/a |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 1.2× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 3.1× | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | 0.2× | -8.9% | -3.4% |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | 1.9× | -4.9% | +0.7% |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 2.5× | 5.7% | +3.3% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | 11.5× | n/a | n/a |